Published in JAMA Surg on August 01, 2015
Kirsten Ras* oncogene: significance of its discovery in human cancer research. Oncotarget (2016) 0.80
KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients. Int J Mol Sci (2016) 0.79
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer (2017) 0.75
Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol (2016) 0.75
MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. Oncotarget (2016) 0.75
Colorectal Liver Metastasis Resection Outcomes Defined by Molecular Biology. JAMA Surg (2015) 0.75
Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surg Oncol (2016) 0.75
Tumor diversity and evolution revealed through RADseq. Oncotarget (2017) 0.75
mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy. Mol Oncol (2016) 0.75
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg (1999) 14.31
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature (1984) 6.21
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol (2009) 4.94
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg (1999) 4.09
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer (2009) 3.73
Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther (2006) 3.56
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol (2012) 2.86
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol (2012) 1.97
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer (2013) 1.94
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract (2009) 1.80
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med (2014) 1.78
K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res (2000) 1.73
Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg (2007) 1.70
Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer (1993) 1.66
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg (2012) 1.60
Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) (2011) 1.44
Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol (1999) 1.41
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg (2013) 1.34
Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg (2008) 1.32
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol (2012) 1.19
Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays. Methods Enzymol (1995) 1.15
Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene (1991) 1.06
Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep (2011) 1.04
BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol (2012) 0.99
Surgery for colorectal liver metastases: The evolution of determining prognosis. World J Gastrointest Oncol (2013) 0.95
Molecular and biochemical markers in colorectal cancer. Ann Oncol (2002) 0.94
Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. Cancer Res (1990) 0.92
All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev (2010) 0.91
Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer (2012) 0.91
Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer (2015) 1.82
Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 535 Patients. JAMA Surg (2015) 1.46
Potential Economic Impact of Using a Restrictive Transfusion Trigger Among Patients Undergoing Major Abdominal Surgery. JAMA Surg (2015) 1.42
Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surg (2016) 1.42
Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer (2014) 0.94
Long-term therapy with sorafenib is associated with pancreatic atrophy. J Surg Res (2015) 0.77
Prognostic impact of complications after resection of early stage hepatocellular carcinoma. J Surg Oncol (2017) 0.75
Risk factors and prediction model for inpatient surgical site infection after major abdominal surgery. J Surg Res (2017) 0.75